Optimization of T cell co-stimulatory agonists: A semi-mechanistic PKPD model integrating drug properties and tumor-immune interactionsCANCER RESEARCHIF16.62024-03-220PRE
Maximizing the outcome of CD226 stimulation through targeting beyond TIGIT signaling with combination and multi-specific approaches for cancer immunotherapyCANCER RESEARCHIF16.62023-04-040PRE
A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomesNATURE COMMUNICATIONSIF15.72021-05-1163OAAI
HFB10-1E1, a novel OX-40 agonistic antibody with a unique pharmacological profile and biomarker strategyCANCER RESEARCHIF16.62020-08-150PRE
A Translocated Effector Required for Bartonella Dissemination from Derma to Blood Safeguards Migratory Host Cells from Damage by Co-translocated EffectorsPLOS PATHOGENSIF4.92014-06-1928OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项